晶华微(688130) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 reached ¥44,547,170.04, representing a year-on-year increase of 21.80% and a quarter-on-quarter growth of 7.13%[6] - The total profit for the period was -¥8,083,937.75, with a net profit attributable to shareholders of -¥7,878,981.97, indicating ongoing financial challenges[4] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -¥2,134.28 million after accounting for share-based payment expenses of ¥949.79 million[9] - The net loss for the first three quarters of 2025 was ¥30,840,706.14, compared to a net loss of ¥7,157,997.60 in the same period of 2024[24] - Basic and diluted earnings per share for the current period were both -¥0.26, compared to -¥0.08 in the previous year[25] Research and Development - Research and development expenses amounted to ¥19,978,188.80 in Q3 2025, accounting for 44.85% of revenue, a decrease of 4.13 percentage points compared to the previous year[5] - R&D investment increased by 31.84% year-to-date due to higher material costs and additional R&D personnel[14] - Research and development expenses rose to ¥66,172,055.52, representing a 31.9% increase from ¥50,193,008.55 in the previous year[23] - The company is focusing on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[23] Market and Product Development - The company successfully acquired Shenzhen Jinghua Zhixin Microelectronics Co., expanding its business scale and actively exploring new markets[6] - The revenue from medical health SoC chip products accounted for 33.97%, with a significant year-on-year increase of 158.35% in sales of blood glucose meter chips[7] - The number of ongoing chip projects increased by 20.59% compared to the same period last year, with a 100% increase in the number of tape-out instances[8] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,346,103,308.12, reflecting a decrease of 5.72% from the end of the previous year[5] - Total assets decreased to ¥1,346,103,308.12 from ¥1,427,803,016.08, reflecting a decline of approximately 5.7%[21] - Total liabilities decreased to ¥99,463,884.16 from ¥162,552,705.21, a reduction of about 38.8%[20] Cash Flow and Liquidity - The company has a total cash balance of approximately ¥151.88 million as of September 30, 2025, down from ¥711.24 million at the end of 2024[18] - The company's cash flow from operating activities showed a significant decline, impacting overall liquidity[25] - The net cash flow from operating activities for the first three quarters of 2025 was -CNY 33,551,116.71, slightly worse than -CNY 31,624,186.57 in 2024[27] - The ending cash and cash equivalents balance for the first three quarters of 2025 was CNY 151,876,634.01, a significant decrease from CNY 555,580,018.75 in 2024[27] - The total cash outflow from operating activities was CNY 181,561,445.33 in 2025, compared to CNY 135,993,263.46 in 2024, reflecting an increase of approximately 33%[27] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 7,974[15] - The largest shareholder, Lü Huanquan, holds 53,158,560 shares, representing 43.97% of total shares[16] - The second-largest shareholder, Luo Luoyi, holds 13,030,290 shares, accounting for 10.78%[16] Government Support - The company received government subsidies amounting to ¥201,000.00, which positively impacted its financial results[11] Investment Activities - The company reported an investment income of ¥8,834,065.67, down from ¥10,295,429.25 year-over-year[23] - The cash inflow from investment activities was CNY 894,845,039.28 in 2025, down from CNY 982,924,971.19 in 2024, a decrease of about 9%[27] - The net cash flow from investment activities was -CNY 484,183,695.70 in 2025, compared to -CNY 163,678,357.95 in 2024, indicating a significant increase in cash outflow[27]